SpyGlass Pharma (SGP) Enterprise Value (2024 - 2026)
SpyGlass Pharma (SGP) posted quarterly Enterprise Value of -$107.4 million for Q4 2025, down 560.41% year-over-year from $23.3 million in Q4 2024, and down 560.41% quarter-over-quarter from -$16.3 million in Q4 2024.
SpyGlass Pharma (SGP) Enterprise Value (2024 - 2026) Analysis & Trends
SpyGlass Pharma (SGP) has reported Enterprise Value for 2 consecutive years, with -$107.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value fell 560.41% year-over-year to -$107.4 million; the TTM figure through Dec 2025 stood at -$107.4 million (down 560.41% YoY), while the FY2025 annual figure was -$107.4 million, down 560.41% from the prior year.
- Enterprise Value retreated to -$107.4 million in Q4 2025 per SGP's latest filing, from -$16.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$16.3 million in Q4 2024 and bottomed at -$107.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | SpyGlass Pharma | 876.29 Mn | 876.29 Mn | - | -234.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -234.19 Mn |
| Dec 31, 2025 | -107.44 Mn |
| Dec 31, 2024 | -16.27 Mn |